Table 1 Patients' characteristics at baseline

Age (years), mean (range)

61 (27–90)

64 (38–91)

Gender (female/male)

30 (42.3)/41 (57.7)

23 (43.8)/27 (56.2)

Melanoma AJCC VII stage

• Stage IV

67 (94.4)

47 (94.0)

• Stage IIIC

3 (4.2)

2 (4.0)

• Stage IIIB

1 (1.4)

1 (2.0)

CNS metastases at baseline

14 (19.7)

14 (28.0)

BRAF status

• Wild-type

56 (78.9)

35 (70.0)

• Mutation

10 (14.1)

12 (24.0)

• NA

5 (7.0)

3 (6.0)

Type of anti-PD-1 agent

• Pembrolizumab

25 (35.2)

18 (36.0)

• Nivolumab

46 (64.8)

32 (64.0)

Line of treatment (anti-PD-1)

• First-line treatment

49 (69.0)

39 (78.0)

• Second-line treatment

22 (31.0)

11 (22.0)

Type of previous therapy

• Ipilimumab

22 (100)

11 (100)

Response rate at first assessment

• Complete response

8 (11.3)

3 (6.0)

• Partial response

16 (22.5)

8 (16.0)

• Stable disease

24 (33.8)

9 (18.0)

• Progression disease

23 (32.4)

30 (60.0)

ECOG PS

• 0/1

63 (88.7)

40 (80.0)

• > 2

8 (11.3)

10 (20.0)

Allergic patients

4 (5.7)

5 (10.0)

Drugs related allergies

3 (4.2)

4 (8.0)

Sseasonal allergies

1 (1.4)

1 (2.0)

Median OS (months)

27.59

19.30

Median PFS (months)

18.05

10.02

M category

• M0

4 (5.6)

2 (4.0)

• M1a

9 (12.7)

7 (14)

• M1b

9 (12.7)

7 (14.0)

• M1c

49 (69.0)

34 (68.0)

LDH

• High

22 (31.0)

17 (34.0)

• Normal

25 (35.2)

23 (46)

• NA

24 (33.8)

10 (20)